Navigation Links
USC researchers investigate protein that protects tumors

A protein that allows breast cancer cells to evade the body's natural immune responses could be a target of future cancer therapies, according to a study by scientists from the Keck School of Medicine of the University of Southern California.

The study, published in the July 1 issue of the American Journal of Pathology, is the first to identify how EphB4 ?a protein that sits on the surface of cells ?functions.

"The important aspect of this study is that ?if we turn the protein [EphB4] off, the tumor cells die, which means that its function helps the cancer cells survive," says Parkash S. Gill, MD, a professor of medicine in the Keck School and the study's senior author.

The scientists used a fluorescent dye attached to the protein's antibody to reveal the protein's location on the tumor cells.

"The first step was to identify whether it's there [on cancer cells] and how often," he explained. "We found that it was present on 60 percent of the tumors ?and it's expressed from the very first stage of the cancer formation."

The next step was to determine EphB4's purpose. What the scientists discovered was that EphB4 serves as a sentry, guarding the tumor cells from any defenses the body deploys to attack them.

"There are means in the body to kill tumor cells," Gill says. "[If] you block those then you give the cells the opportunity to survive and grow." Not only did EphB4 block those defenses, but it helped the cancer cells flourish by issuing a call for more blood vessels ?the biological equivalent of food for the tumor.

"The tumor cell carrying this protein ?on its surface communicates with blood vessels nearby," Gill says. "It sends the signal for more blood vessels to grow. One key item for any cancer to grow is to include more blood vessels."

The goal of a future anti-cancer therapy would be to block the protein, essentially knocking out one of the tumor cell's guardians. A similar approach wa s used to develop Herceptin, one of the first biological treatments for breast cancer. Herceptin targets the her2 protein, which is found on the surface of tumor cells about 20 percent of the time, says Gill.

The her2 protein played a role in this study as well. That protein, along with several of its cousins, was found to activate EphB4, he said. "There are certain growth factors that can make this particular protein (EphB4) go up," Gill says. "We are learning more about how this protein is turned on and off in a cancer cell."


'"/>

Source:University of Southern California


Related biology news :

1. NYU researchers simulate molecular biological clock
2. Vital step in cellular migration described by UCSD medical researchers
3. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
4. UCSD researchers maintain stem cells without contaminated animal feeder layers
5. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
6. New protein discovered by Hebrew University researchers
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Agilent Technologies releases automated literature search tool for biology researchers
9. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
10. Yale researchers identify molecule for detecting parasitic infection in humans
11. US life expectancy about to decline, researchers say
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Island, NY (PRWEB) , ... February 24, 2017 , ... ... rate. Founded in late 2014, FireflySci had the goal of bringing their powerful ... that goal continues to shape the path that FireflySci is going on as they ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring ... home or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor ...
Breaking Biology Technology: